Rezolute (NASDAQ:RZLT – Free Report) had its price target raised by Citizens Jmp from $11.00 to $15.00 in a report issued on Tuesday,Benzinga reports. They currently have a market outperform rating on the stock.
A number of other analysts have also issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rezolute in a report on Friday, July 17th. Lake Street Capital assumed coverage on Rezolute in a research note on Wednesday, September 30th. They set a “buy” rating and a $9.00 price target on the stock. Guggenheim lifted their price objective on Rezolute from $6.00 to $11.00 and gave the company a “buy” rating in a report on Monday, June 15th. Zacks Research raised shares of Rezolute from a “strong sell” rating to a “hold” rating in a research note on Friday, August 14th. Finally, HC Wainwright increased their target price on shares of Rezolute from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, September 25th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Rezolute currently has a consensus rating of “Moderate Buy” and an average price target of $11.22.
View Our Latest Report on RZLT
Rezolute Price Performance
Rezolute (NASDAQ:RZLT – Get Free Report) last posted its earnings results on Thursday, September 24th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05). On average, research analysts anticipate that Rezolute will post -0.63 EPS for the current year.
Institutional Trading of Rezolute
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Auxano Advisors LLC acquired a new stake in shares of Rezolute in the second quarter valued at approximately $52,000. Sequoia Financial Advisors LLC bought a new position in shares of Rezolute in the second quarter worth $75,000. WINTON GROUP Ltd bought a new position in shares of Rezolute in the second quarter worth $88,000. Integrated Wealth Concepts LLC bought a new stake in shares of Rezolute during the second quarter valued at about $143,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Rezolute in the first quarter worth about $90,000. 82.97% of the stock is currently owned by institutional investors and hedge funds.
About Rezolute
Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. The company’s research is centered on conditions involving abnormal insulin signaling and glucose regulation, including rare disorders and complications associated with diabetes.
Rezolute’s lead investigational product is RZ358, a human monoclonal antibody designed to reduce the effects of excessive insulin activity. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas releases too much insulin and causes potentially dangerous episodes of low blood sugar.
See Also
- Five stocks we like better than Rezolute
- Want Private-Market Access to Kalshi and Polymarket? Try This ETF
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.
